Investigation of the Impact of Medicati… | Clinical Trial

Key information

Conditions

Hearing COVID - 19 COVID-19 Chemically-Induced Disorders Coronaviridae Infections Coronavirus Infections Drug-Related Side Effects and Adverse Reactions Ear Diseases Infections Lung Diseases Nidovirales Infections Otorhinolaryngologic Diseases Ototoxicity Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral RNA Virus Infections Radiation Injuries Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases Wounds and Injuries

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Biruni University

Istanbul, Turkey (Türkiye)

About this study

This study aims to investigate the impact of medications containing the active ingredients hydroxychloroquine and favipiravir on the auditory system, as well as to examine the effect of COVID-19 on hearing and its potential relationship with medication use and COVID-19 vaccine dose.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age between 18 and 35 For the Medication group: Having had COVID-19 and using COVID-19 medications For the Non-Medication group: Having had COVID-19 and not using COVID-19 medications For the Control group: Having never had COVID-19

Exclusion criteria

Previously diagnosed with hearing loss Use of ototoxic medications other than those specified Pathology detected during tympanometric evaluation or otoscopic examination Chronic disease Family history of hearing loss History of meningitis Neurological disorders Acute or chronic ear infection Admission to intensive care

Treatment and study plan

Hearing tests

Diagnostic Test

Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.

Primary outcomes

Pure tone and high frequency hearing thresholds

Time frame: December, 2021-February 2022
Transient evoked otoacoustic emissions - Signal/noise ratio

Time frame: December, 2021-February 2022
Distortion product otoacoustic emissions- signal/noise ratio

Time frame: December, 2021-February 2022

Sponsors and collaborators

Lead sponsor

Zonguldak Bulent Ecevit University

Other

Registry information

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Nov 28, 2025
Registry last updated: Nov 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed